Bexsero regulatory update

Novartis said FDA approved an extended treatment IND from the U.S. Centers for Disease Control to use Bexsero to combat an outbreak of meningococcal disease caused by Neisseria meningitides serogroup B at the University of California, Santa Barbara, which has had 4 confirmed cases of the disease since November. The vaccination program at UCSB began Feb. 24 and will end March 7. Last November, FDA approved use of Bexsero in response in an outbreak of meningococcal disease at Princeton University (see BioCentury, Nov. 25, 2013). ...